Skip to main content
Clinical Trials/JPRN-jRCTs031230208
JPRN-jRCTs031230208
Recruiting
未知

A multicenter, randomized, open-label, drug-controlled, parallel-group study to evaluate the efficacy and safety of enteral nutrition containing highly fermentable dietary fiber in patients with acute ischemic stroke

Kurita Naohide0 sites38 target enrollmentJuly 6, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Acute ischemic stroke
Sponsor
Kurita Naohide
Enrollment
38
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 6, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kurita Naohide

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients who are 20 years of age or older at the time consent is obtained
  • 2\) Patients admitted with a diagnosis of acute ischemic stroke within 48 hours of onset
  • 3\) Patients with acute ischemic stroke confirmed by head MRI diffusion\-weighted imaging
  • 4\) Patients with dysphagia who require enteral nutrition
  • 5\)Patients who have the capacity to consent and are able to obtain the written consent of their own free will or patients who have difficulty in obtaining written consent due to impaired consciousness or other reasons. If the patient is unable to give consent due to impaired consciousness or other reasons, the patient must be able to obtain written consent from a surrogate (20 years of age or older, within the second degree of kinship).
  • (6\) Patients who are judged by the principal investigator (sub\-investigator) to be capable of adequately evaluating the efficacy and safety of the study, taking into consideration the selection and exclusion criteria.

Exclusion Criteria

  • 1\) Patients with pneumonia or other infectious diseases for which enteral nutrition is inappropriate
  • 2\) Patients with severe renal disease (serum creatinine level \> 2\.0 mg/dL)
  • 3\) Patients with serious hepatic disorder (AST or ALT \> 100 U/L)
  • 4\) Patients with serious cardiac disease
  • 5\) Patients with milk allergy (allergy to milk protein and whey)
  • 6\) Patients with diarrhea of any kind
  • 7\) Other patients deemed inappropriate as research subjects by the principal investigator (or sub\-investigator)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 4
A multicenter, randomized, open, positive drug parallel controlled clinical trial on the efficacy and safety of Pien Tze Huang Capsule combined with Compound Pien Tze Huang Hemorrhoid Ointment after operration of mixed hemorrhoidsAfter operration of mixed hemorrhoids
ITMCTR2200006491Jiangsu Provincial Hospital of Chinese Medicine
Active, not recruiting
Not Applicable
An open-label, randomized, multicenter, clinical study to comparethe effects of telithromycin, azithromycin and cefuroxime axetilon the penicillin or macrolide resistance of Streptococcus pneumoniaein patients with acute exacerbation of chronic bronchitis - Perspective
EUCTR2004-001412-30-HUaboratoire Aventis5,660
Active, not recruiting
Not Applicable
A randomised, open-label, single-centre, pharmacokinetic study of a single dose of lorazepam administered by the intranasal and buccal route in healthy adult volunteers - Lorazepam Pharmacokinetics after Intranasal and Buccal AdministratioStatus epilepticusMedDRA version: 9.1Level: LLTClassification code 10041962Term: Status epilepticus
EUCTR2008-001575-30-GBniversity of Nottingham12
Not yet recruiting
Not Applicable
A phase I, multi-center, open-label, drug-drug interaction study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on TKI258 (dovitinib) pharmacokinetics in patients with advanced solid tumors.advanced cancersolid tumors10027655
NL-OMON39285ovartis12
Unknown
Phase 1
Phase I/II study of OPB-31121 in patients with progressive hepatocellular carcinoma
JPRN-jRCT2080221507Otsuka Pharmaceutical Co., Ltd.